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ing years per 1,000 patients. Predicted UK-wide benefits included the avoidance of 
2,097 transplants, 994 access procedures, approximately 2.5 million haemodialysis 
sessions and more than 900,000 peritoneal dialysis days, with gains of 71,500 QALYs, 
78,800 life years and 86,045 working years. ConClusions: ADPKD-associated ESRD 
represents a significant burden to both patients and healthcare systems. Delaying 
disease progression through treatment could meaningfully impact this burden, 
reducing healthcare resource use, requirement for donor organs and the negative 
impact upon quality-of-life, life-expectancy and productivity.
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objeCtives: Cardiovascular deterioration and renal dysfunction are significant 
complications for some muscular dystrophy (MD) patients. Although MD patients 
with cardiovascular problems may benefit from ACE-inhibitor treatment, there 
is some debate about whether this therapy is safe for use in patients with renal 
dysfunction. The objective of this study was to describe ACE-inhibitor treatment 
among MD patients with severe renal dysfunction, as they may be the most likely 
candidates for contraindication. Methods: We identified two cohorts of individu-
als aged 0-64 with a muscular dystrophy diagnosis between 1/1/2009 and 10/31/2013 
or 1/01/2009 and 10/31/2011 from an administrative claims database. Patients were 
continuously enrolled with benefits for 12 and 36 months, respectively, after the 
index date, defined as the first date of evidence of severe renal dysfunction--chronic 
kidney disease, renal failure or end stage renal disease. Subsequent ACE-inhibitor 
use was evaluated in the 12 and 36 months after index date. Results: A total of 
11,515 MD patients with 12 months continuous enrollment, and 4,547 individuals 
with MD and 36 months continuous enrollment were identified, of which 14 -20% 
filled at least one prescription for an ACE-inhibitor. There were 340 (3%) patients 
with 12 months enrollment who had evidence of severe renal dysfunction, and 127 
(37%) of those filled a subsequent prescription for an ACE-inhibitor. There were 94 
(2%) patients with 36 months enrollment who had evidence of severe renal dys-
function, of which 50 (53%) filled at least one subsequent prescription for an ACE-
inhibitor. ConClusions: Cardio-protective treatment with ACE-inhibitors among 
MD patients is significant. Although severe renal dysfunction is not highly prevalent 
in this population, 36%-49% with the condition were treated with an ACE-inhibitor, 
despite a possible contraindication, especially in patients with severe disease. New 
therapies in development which address underlying disease rather than complica-
tions may enable patients to avoid potential contraindications.
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objeCtives: Fingolimod oral tablets were approved in the United States (US) in 
September 2010 for the treatment of relapsing remitting multiple sclerosis (RRMS). 
The objective of this study is to assess the costs associated with Fingolimod treat-
ment for patients diagnosed with RRMS in the US. Methods: A large US adminis-
trative retrospective claims database was used to identify patients diagnosed with 
RRMS and were prescribed Fingolimod between January 2010 to December 2012 were 
included in the study. All patients were ≥ 18 years of age and continuously enrolled 
in the same health plan for a year. Descriptive statistics and chi-square tests were 
performed on the data. Results: There were a total of 28,477 patients that met 
the study inclusion criteria. Patients on average were charged $5270.93 ± 2760.33 
for their treatment with Fingolimod during the study period. However, the allowed 
amount by the health plan was $4624.41 ± 2070.65 and the actual paid amount was 
$4529.98 ± 2074.58. On average, patient’s deductible was $13.64 ± 186.88 and patient 
co-payment was $86.33 ± 316.10. For patients whose prescription was on their health 
plans formulary paid on average higher costs compared to patients who were not 
(paid amount $4679 vs $4317). Even though most of the patients were females, but 
they had overall lower costs compared to males (amount charged $4513 vs $4582, 
p> 0.05; co-payment $79 vs $106, p< 0.05). Patients who received treatment in the 
Midwest region of the USA had a higher costs compared to east, west and south 
regions (paid amount $4618 vs $4608 vs $4370 vs $4405). ConClusions: The cost 
of Fingolimod treatment for RRMS patients is higher and costing the health plan 
around $3552 for 3 months. The cost of the drug treatment was higher in southern 
of the USA and males were paying more in general.
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objeCtives: Fingolimod is an orally available immune-modulatory drug for treat-
ing relapsing-remitting Multiple Sclerosis (RRMS). It was approved by the European 
Medicines Agency (EMA) in March 2011. Some urgent safety warnings (e.g. progres-
sive multifocal leukoencephalopathy (PML) and cardiovascular events) have been 
reported in the meantime. Early benefit assessment by the Federal Joint Committee 
(G-BA) in 2012 and 2013 showed only additional benefit for a certain subgroup of 
patients. Therefore the use of Fingolimod has widely been discussed in Germany. 
We analyzed prescriptions of Fingolimod and the impact of Health Technology 
Assessment (HTA) and drug safety warnings. Methods: We used routine data of 
the Techniker Krankenkasse (TK), a large German sickness fund with more than 
8.2 million insured, from 2012 to 2014. We looked for prescriptions of disease-
modifying therapies (DMT) for patients with Multiple Sclerosis (MS). Diagnosis of 
MS was identified by G35 according to ICD-10. Considered DMT were Fingolimod, 
Glatiramer Acetate, Alemtuzumab, Natalizumab, Interferon beta-1a, Interferon beta-
between treatment groups. Differences reflected the known efficacy and safety 
profile of BRV. Where reported for other AEDs, changes from baseline and treatment 
group differences are similarly small, raising questions about the appropriateness of 
short-term fixed-dose trials as a source of HRQoL data for adjunctive AEDs in refrac-
tory patients. Long-term assessments may be more informative. Supported by UCB.
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objeCtives: The aim of this paper is to analyze pharmaceutical expenditure in 
Alzheimer patients from a Europe southeastern region (Valencian Region (Spain)), 
by using the clustering patients system Clinical Risk Group (CRGs). We focused on 
obtaining more information about Alzheimer patients, stablishing a more accurate 
prediction of their resources consumption and individuating patterns of pharma-
ceutical consumption. Methods: A cross-sectional study of the inhabitants of 
Valencian region with a population of 5,000,000 was carried out, using data extracted 
from Electronic Health Records for 2013. A sample of 24641 Alzheimer individuals 
were identified. Results: From our sample 29.4% men and 70.6% women were 
found. The annual average cost per Alzheimer patient is € 1709.051. By gender, 
women average cost is 1718,66 € while men average consumption is 1685,97 € . Age 
is the variable which most affect pharmaceutical cost variability, while severity 
levels are not capable to explain cost variability. ConClusions: Valuable informa-
tion about pharmaceutical cost of Alzheimer patients was found. In contradiction 
to other diseases, for the Alzheimer case, levels of severity does not provide a clear 
explanation of pharmaceutical cost variability.
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objeCtives: Transition from RRMS to SPMS is difficult to diagnose. Here, we describe 
methodology for developing a screening tool that can help physicians to diagnose 
SPMS early. Methods: Tool will be developed along 3 steps: Quantitative research: A 
retrospective cross-sectional study to describe differentiating characteristics between 
SPMS and late RRMS patients using Adelphi Real World database. 2791 MS patient 
record forms from 125 neurologists (US) are available. Key variables will include demo-
graphics, MS history, treatment history, daily activities, symptoms and clinical charac-
teristics including MRI activity. Patients will be stratified based on EDSS and disease 
duration into: Early RRMS (control group), Late RRMS and Early SPMS. A multivariate 
regression analysis will identify the significant predictors of patient classification 
as ‘Late RRMS’ or ‘Early SPMS’ by physician. Qualitative research: (1) Open-ended 
qualitative interviews of patients (16 each in the US and Germany—8 RRMS and 8 
SPMS/country) and treating clinicians (8/country) to identify and characterize key 
differentiating features of these two MS phenotypes. (2) Integrating interviews with 
quantitative research to draft the tool. (3) Use of draft version by physicians treating 
SPMS patients. (4) Cognitive debriefing with physician. Tool validation: Sensitivity 
and specificity will be validated against reference tests in a 12Month prospective 
observational study in patients with late RRMS and SPMS after the implementation of 
the tool. Results: Data collected will be used to generate a paper version of the tool 
that will track the disease experience of late RRMS patients periodically (relapse and 
recovery, symptoms, quality of life). After validating the paper version, an electronic 
version will be considered. A calculator will be added to the tool to predict likelihood 
of patient progression to SPMS. ConClusions: Such a validated tool is expected to 
support physicians in more accurate and timely identification of SPMS patients to 
provide optimized clinical intervention.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is charac-
terised by enlarged kidneys, declining renal function and ultimately progression 
towards end-stage renal disease (ESRD), with significant mortality, co-morbidity 
and resource implications. This study aimed to quantify the humanistic and health 
system burden of ADPKD in the UK, and the potential impact of ADPKD treatment 
that may delay progression to ESRD. Methods: ADPKD progression was predicted 
over a 50-year horizon using the ADPKD Outcomes Model. Patient profiles consistent 
with the CRISP longitudinal ADPKD outcomes trial were modelled using regression 
equations for renal decline derived from the TEMPO 3:4 study placebo arm. ESRD 
rates were drawn from UK published sources. Treatment-related reduction in the 
rate of renal decline was based on TEMPO 3:4 (tolvaptan: 31.6%). ESRD outcomes, 
quality-adjusted life-years (QALYs) and life-years accumulated were reported per 
1,000 patients, and scaled to the UK population. Results: Without treatment, 927 
incident ESRD events were predicted per 1,000 patients; corresponding to 372 inci-
dent transplants, 435 dialysis access procedures and 4,707 dialysis years. Treatment 
was estimated to prevent 61 ESRD events per 1,000 patients, thereby avoiding 82 
transplants, 39 access procedures and 707 dialysis years, and accruing an additional 
2,788 QALYs and 3,075 life-years (undiscounted). Delay of ESRD beyond retirement 
age (65 years) was predicted in 16.6% of treated patients with 3,356 additional work-
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ADD cut-point was based on the ineffectiveness of DF in reducing the number of 
new brain lesions at doses < 360 mg/day.1 Results: The study sample consisted of 
2,879 patients; 19.8% relapsed within 9 months, with an average time to relapse of 
110 days (standard deviation: 77.9). A higher proportion of non-adherent patients 
relapsed versus adherent patients (23.4% vs. 17.9%; p= 0.0004). A higher propor-
tion of patients with suboptimal ADD experienced relapse compared with those 
with ADD ≥ 360 mg/day (26.7% vs. 17.9%, p< 0.0001). Non-persistence was associ-
ated with a higher occurrence of relapse compared with persistence (25.0% vs. 
18.2%, p= 0.0001). ConClusions: Non-adherence and suboptimal dosing with DF 
were related to higher relapse rates in MS patients in a real-world setting. Further 
research is needed to confirm these findings for other DMTs and to quantify the 
level of non-adherence with its impact on effectiveness.REFERENCES: 1. Kappos 
L, et al. Lancet. 2008;372:1463-72. 2. Chastek BJ, et al. J Med Econ. 2010;13:618-25.
ReFeRenCes:
1. Kappos L, et al. Lancet. 2008;372:1463-72.
2. Chastek BJ, et al. J Med Econ. 2010;13:618-25.
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objeCtives: Multiple sclerosis (MS) is an acquired chronic immune-mediated 
inflammatory condition of the central nervous system. It is the commonest cause 
of serious physical disability in adults of working age. Inequalities in access to 
treatment and care for MS have been recognised within the UK and when the UK 
is compared with Europe eg. 69% of patients in Germany have access to disease 
modifying therapies versus 21% of patients in the UK. Recent NICE guidance has 
been issued to tackle the inequalities in access to care for MS in England, however 
uptake of NICE Guidance is not uniform across the country, leading to delays and 
restrictions in access to treatment for patients in some areas. This paper aims to 
assess the current variation in access to treatment for MS in England. Methods: 
Prescribing of fingolimod for MS in England was examined using the NHS England 
Innovation Scorecard for Key Secondary Care Medicines per 100,000 population. 
Uptake of fingolimod across the 25 area teams was examined. Results: Despite 
positive NICE guidance for fingolimod issued in April 2012 there are major differ-
ences in the uptake of fingolimod in England. The highest uptake can be seen in 
the London area and in other area team geographies in the south. Uptake in these 
areas is at least 3 fold and in some cases 7 fold greater than that seen in area team 
geographies in the North West. Some of this variation may be explained by proximity 
to specialist care centres, however the existence of these centres does not explain 
the extent of the variation. ConClusions: Variations in access to treatment for 
MS in England persist despite NICE guidance and NHS reform aimed at addressing 
these inequalities.
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objeCtives: Multiple Sclerosis (MS) is a progressive and debilitating condition with 
long-term impacts on patients and healthcare resources. Natalizumab is a disease-
modifying biologic used in MS and administered by intravenous infusion every 28 
days. This analysis evaluated the impact of natalizumab on hospital activity using 
Hospital Episodes Statistics (HES) data. Methods: A retrospective analysis of HES 
was performed using data for the specific period January 2010 to May 2012 (29 
consecutive months). Data after May 2012 was not used due to the introduction of 
a second drug which could not be differentiated from natalizumab. A systematic 
HES coding search identified patients via ICD and OPCS codes and patterns of hos-
pital attendance. Attendances were collated for the period from 6 months pre- and 
6 months post- natalizumab initiation. Healthcare utilisation metrics included: 
number of planned & unplanned hospital visits, planned & unplanned bed days, 
and outpatient appointments. Results: Comparing pre- with post- natalizumab 
periods there was a 50.0% reduction in mean unplanned hospital visits per patient (p 
= 0.010) and a 49.6% reduction in the mean number of bed days per unplanned visit 
(p = 0.027). Other observations included a 74.8% reduction in the mean number of 
unplanned bed days per patient (p = 0.138) and a 44.8% increase in mean outpatient 
appointments per patient (p = 0.351) however these were not statistically significant. 
As expected, natalizumab was associated with an increase in planned admissions 
although the mean number of bed days per planned admission was reduced by 
87.0% (p = 0.004). The changes to in-patient admissions were estimated to deliver a 
small reduction in healthcare expenditure. ConClusions: The pattern of changes 
in hospital activity associated with natalizumab support the expected positive clini-
cal outcomes. Confounding aspects were an identification bias in the non-random 
sampling and the potential for a regression to the mean effect.
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objeCtives: There is currently no cure for Duchenne muscular dystrophy (DMD), 
which results in progressive paralysis and death generally in early adulthood. 
Available treatments only address symptoms, with limited success. However, sev-
eral new therapies targeting underlying genetic components of the disease have 
passed pre-clinical phases of drug development. In anticipation of new therapies 
coming to market, we sought to examine current treatment patterns, resource 
1b, Peginterferon beta-1a, Teriflunomide, Dimethyl Fumarate and Azathioprine, 
detected by ATC Code. We extrapolated results to whole SHI by adjusting for dif-
ferences in demographics of insured between TK and SHI. Results: G-BA issued 
additional benefit of Fingolimod only for patients with rapidly evolving severe RRMS, 
i.e. 1.500 patients in Germany. We observed 9.538 patients with MS and prescrip-
tion of Fingolimod in SHI in 2013 and 11.085 in 2014, corresponding to about every 
10th patient with MS and prescription of DMT. Total outpatient pharmaceutical 
expenditure for DMT was million € 1,843 in 2014, million € 210 (11.4%) caused by 
Fingolimod. ConClusions: HTA and drug safety warnings don´t seem to influence 
prescribing behaviour. This might be accompanied by additional costs for SHI and 
doubtful benefit for patients. Whether marketing or patient demand is responsible 
for over-prescription needs to be discussed elsewhere.
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objeCtives: Fingolimod oral capsules were the first oral disease modifying agent 
(DMT) approved in the United States (US) in September 2010 for the treatment of 
relapsing remitting multiple sclerosis (RRMS). The objective of this study is to assess 
the characteristics of RRMS patients taking Fingolimod capsules in the US. Methods: 
A large US administrative retrospective claims database was used to identify patients 
diagnosed with RRMS and were prescribed Fingolimod between January 2010 to 
December 2012 were included in the study. All patients were ≥ 18 years of age and 
continuously enrolled in the same health plan for a year. Descriptive statistics and 
chi-square tests were performed on the data and statistical significance level was 
set a priori at 0.05. Results: There were a total of 28,447 patients that met the study 
inclusion criteria. Of these, 21,629 (75.9%) were females, mean age was 49.1±10.0 
years, and males were older than females (49.78 vs 48.9 years; P< 0.001) with a sta-
tistical significance different between them. Thirty four percentage of the patients 
were from Midwest, 25.5% were from East, 34.4% from south and 5.2% from West of 
the USA. Thirty three percentage of the patient’s prescription was with their health 
plan formulary and received an average of supply of 31.6 ± 13.6 days. Majority (60.9%) 
of the patients was under group coverage and 59.1% of patients were diagnosed 
with having mental health problems. Females enrolled continuously (5.1 ± 2.4 vs 
5.0 ± 2.4 years) much longer than males in the same health plan. But, females had a 
higher number of total claims (488.2 ± 389.0 vs 416.6 ± 389.0) during the enrollment 
period. ConClusions: Majority of the patients taking Fingolimod was females and 
had more number of claims related to MS than males. And, majority of the patients 
were dispensed Fingolimod for only one month supply.
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objeCtives: The objective of this study is to assess the characteristics of relapsing 
remitting multiple sclerosis patients taking disease modifying therapies (DMTs) in 
the US. Methods: A large US administrative retrospective claims database was 
used to identify patients diagnosed with Multiple Sclerosis (MS) and were pre-
scribed DMTs between January 2010 to December 2012 were included in the study. 
All patients were ≥ 18 years of age and continuously enrolled in the same health 
plan for a year. Descriptive statistics and chi-square tests were performed on the 
data and statistical significance level was set a priori at 0.05. Results: There were 
a total of 741,065 patients that met the study inclusion criteria. The mean age of the 
patients was 52.38 ± 10.50 years, 75.7% of the patients were females, and majority 
of the patients were between 41 to 64 years of age (73.5%). Thirty two percent of 
the patients were from East, 34.6% were from Midwest, 25% from South and 7.8% is 
from West region. 56.6% of the patients were on a group coverage plan and 62.6% of 
the patients were on a DMT prescription that is under their health plan formulary. 
Majority of the patients (92.9%) were prescribed 30 days’ supply of DMTs, 6.3% 
were on 90 days’ supply and only 0.8% were on 60 days’ supply of DMTs. More 
than half of the patients (55.7%) were diagnosed with mental health problems in 
addition to their RRMS as a primary diagnosis. On average, patients were continu-
ously enrolled for 5.36 ± 2.40 years and submitting around 446 claims during this 
period. ConClusions: The majority of the patients was females and was between 
41 to 64 years of age. And majority of the patients received 30 days’ supply of DMTs.
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objeCtives: To explore the relationship between medication-use patterns of mul-
tiple sclerosis (MS) disease-modifying therapy (DMT) and relapse in a real-world 
setting. Methods: This was a retrospective, observational study using administra-
tive claims data. Dimethyl fumarate (DF), a DMT, was selected for analysis due to 
availability of medication-dosing data in relation to efficacy observed in a clinical 
trial.1 Adult MS patients with DF claims (March 2013–January 2014) continuously 
enrolled for 9 months before and after therapy initiation were included. A validated 
algorithm was used to define relapse by either an inpatient claim with a primary 
MS diagnosis or a systemic corticosteroid claim within 7 days of an MS outpa-
tient visit.2 Medication-use patterns were assessed by non-adherence (medica-
tion possession ratio (MPR) < 0.90), suboptimal average daily dose (ADD < 360 mg/
day), and treatment non-persistence (DMT switch or ≥ 30-day gap in therapy). The 
